Romidepsin is a histone deacetylase (HDAC) inhibitor and anti-tumor drug approved by the Food and Drug Administration (FDA) for the treatment of cancer T-cell lymphoma (CTCL) [73, 74]. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.